Press Releases

Press Releases

    Date Title View
    12/23/21
    Summary ToggleHorizon Therapeutics plc to Participate in Upcoming Investor Conferences
    PDF Version
    12/16/21
    Summary ToggleAlpine Immune Sciences and Horizon Therapeutics plc Announce Exclusive License and Collaboration Agreement to Develop Novel Protein-Based Therapies for Autoimmune and Inflammatory Diseases
    PDF Version
    12/02/21
    Summary ToggleHorizon Therapeutics plc Makes $100,000 Seed Donation to Support Fundraising Efforts to Renovate Emmett Till’s Home into a Museum and Theater
    PDF Version
    12/02/21
    Summary ToggleGreat Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List
    PDF Version
    12/01/21
    Summary ToggleHorizon Therapeutics plc Provides Academic Scholarships to Help Economically Disadvantaged Students in Ireland Further Their STEM Education
    PDF Version
    11/22/21
    Summary ToggleNew Analysis Published in Multiple Sclerosis and Related Disorders Supports the Efficacy of UPLIZNA® (inebilizumab-cdon) in Patients Previously Treated with Rituximab for Neuromyelitis Optica Spectrum Disorder (NMOSD)
    PDF Version
    11/15/21
    Summary ToggleHorizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative
    PDF Version
    11/12/21
    Summary ToggleNew Real-World Data Show High Rate of Patient Adherence to TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED)
    PDF Version
    11/12/21
    Summary ToggleHorizon Therapeutics plc Receives CHMP Positive Opinion for UPLIZNA® (inebilizumab) as a Monotherapy for the Treatment of Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
    PDF Version
    11/09/21
    Summary ToggleHorizon Therapeutics plc Announces First Patient Enrolled in Phase 2b Pivotal Trial Evaluating HZN-825 for the Treatment of Diffuse Cutaneous Systemic Sclerosis
    PDF Version
    Displaying 1 - 10 of 74 results